Your browser doesn't support javascript.
loading
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge, Regine; Wittig, Tim; Georgi, Thomas W; Kurch, Lars; Sabri, Osama; Wallace, W Hamish; Klekawka, Tomasz; Fernández-Teijeiro, Ana; Ceppi, Francesco; Karlén, Jonas; Pears, Jane; Cepelová, Michaela; Fosså, Alexander; Beishuizen, Auke; Hjalgrim, Lisa Lyngsie; Körholz, Dieter; Mauz-Körholz, Christine; Hasenclever, Dirk.
Affiliation
  • Kluge R; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany regine.kluge@medizin.uni-leipzig.de.
  • Wittig T; Department of Internal Medicine, University Hospital of Leipzig, Leipzig, Germany.
  • Georgi TW; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.
  • Kurch L; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.
  • Sabri O; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany.
  • Wallace WH; University of Edinburgh and Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom.
  • Klekawka T; Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, and Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
  • Fernández-Teijeiro A; Department of Pediatric Oncology and Hematology, University Hospital Virgen Macarena, Sevilla, Spain.
  • Ceppi F; Pediatric Hematology-Oncology Unit, Division of Pediatrics, Woman-Mother-Child Department, University Hospital of Lausanne, Lausanne, Switzerland.
  • Karlén J; Pediatric Cancer Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Pears J; Our Lady's Children's Hospital, Dublin, Ireland.
  • Cepelová M; Department of Pediatric Hematology and Oncology, Faculty Hospital Motol, Prague, Czech Republic.
  • Fosså A; Department of Medical Oncology and Radiotherapy, Rikshospitalet-Radiumhospitalet, Oslo, Norway.
  • Beishuizen A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Hjalgrim LL; Department of Childhood and Adolescence Medicine, Department of Pediatric Hematology and Oncology, Juliane Marie Center, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Körholz D; Department of Pediatric Oncology and Hematology, University Hospital Giessen and Marburg, Giessen, Germany; and.
  • Mauz-Körholz C; Department of Pediatric Oncology and Hematology, University Hospital Giessen and Marburg, Giessen, Germany; and.
  • Hasenclever D; Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany.
J Nucl Med ; 62(3): 338-341, 2021 03.
Article in En | MEDLINE | ID: mdl-32764122
ABSTRACT
In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment.

Methods:

We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments.

Results:

Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable.

Conclusion:

The findings support that first- and second-line treatments in HL do not require different response criteria.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Disease Progression / Positron-Emission Tomography Type of study: Clinical_trials Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: J Nucl Med Year: 2021 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Disease Progression / Positron-Emission Tomography Type of study: Clinical_trials Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: J Nucl Med Year: 2021 Type: Article Affiliation country: Germany